{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL76_IsKDA","founded_year":2000,"lastupdate":"2023-03-16T00:00:00.000Z","update_date":"2023-03-16T00:00:00.000Z","lastModified":"Oct 5, 2024","confidence_score":76,"active":1,"confidence_score_reason":"product stage, sector, business model, video or image, funding rounds, markets","urlname":"phibro-animal-health","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Jan, 1970;","acquired":0,"description_edited":0,"tag_line_edited":1,"phone":"+972732700322","registrar":null,"biverification":"Yanina Wainscheinker","recentupdates":[{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:55:32.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:58:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:52:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:40:18.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 16:12:56.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:07:29.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 04:57:56.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:57:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:37:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:49:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:49:03.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"michalseror@gmail.com","source":"Manual","datetime":"2024-10-05 20:18:23.000000","last_name":"Seror","first_name":"Michal"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:57:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:39:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:40:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:22:12.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:31:09.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:45:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:48:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:45:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:42:49.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:41.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:31:57.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:33:36.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-12-24 07:15:35.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-12-24 07:15:35.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-12-24 07:15:35.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"idit.rech@gmail.com","source":"Manual","datetime":"2017-12-21 15:21:02.000000","last_name":"Benudiz","first_name":"Idit"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:40.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:20:47.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:31:34.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:31:34.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:31:34.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:33:21.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-12-23 14:01:20.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"idit.rech@gmail.com","source":"Manual","datetime":"2017-12-14 16:02:38.000000","last_name":"Benudiz","first_name":"Idit"},{"email":"idit.rech@gmail.com","source":"Manual","datetime":"2017-12-14 16:02:13.000000","last_name":"Benudiz","first_name":"Idit"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-12-23 14:02:45.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-12-23 14:02:45.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-08-26 19:52:40.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:09:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:09:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:09:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:09:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:19:40.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:13:53.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-14 09:13:53.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:42.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:40.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:43.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:31:50.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"meytal.rosh@pahc.com","source":"Manual","datetime":"2017-12-21 15:34:46.000000","last_name":"Bendheim","first_name":"Jonathan"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2017-07-24 06:03:50.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:07.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:08.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:57:35.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:07.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:01:57.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:23:22.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:23:22.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:23:22.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:02:26.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:54:38.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:50:08.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:09.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:57:13.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:57:13.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:39:46.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:39:46.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:39:46.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:39:46.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:57:12.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-24 16:42:55.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-01-29 07:46:42.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:49:10.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:33:30.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:30:34.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:40:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:37:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-24 16:41:02.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-24 16:41:02.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-24 16:41:02.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-24 16:41:02.000000","last_name":"McCandless","first_name":"Katie"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:47:01.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:51:49.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:57:12.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:08.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:26:07.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:41:21.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:03:24.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:50:52.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 07:59:13.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:01:41.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-08 08:40:44.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:40:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:33:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:28:30.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:25:20.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:37:53.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:38:27.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:38:52.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:49:48.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:43:34.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:43:34.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:53:33.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:44:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:11:02.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:44:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:38:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:30:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:30:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-17 09:30:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-11-17 07:19:29.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"hilla.gorokhovsky@sncentral.org","source":"Manual","datetime":"2019-06-05 15:08:44.000000","last_name":"Gorokhovsky","first_name":"Hilla"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:16:45.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:16:45.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:16:56.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-21 14:00:05.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-21 14:00:05.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-21 14:00:05.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:00.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:21.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 14:36:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:16.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 18:02:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 18:02:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:58:33.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:22:33.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"hilla.gorokhovsky@sncentral.org","source":"Manual","datetime":"2019-06-05 15:09:03.000000","last_name":"Gorokhovsky","first_name":"Hilla"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:14:05.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:16:55.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:16:55.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:29.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:18.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 17:18:23.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:45:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:52:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:45:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:41:41.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:40:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:39:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"michalseror@gmail.com","source":"Manual","datetime":"2024-10-05 20:18:23.000000","last_name":"Seror","first_name":"Michal"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:07:29.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-27 18:42:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:57:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:58:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-03-20 06:31:34.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:37:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-02-13 06:54:59.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:39:51.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:09:07.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-16 09:58:22.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2019-10-15T00:00:00.000Z","crunchbaseid":"phibro-animal-health","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Natalia Golczar","creator_email":"ngolczar@gmail.com","createdate":"2016-11-08T00:00:00.000Z","lastupdatedate":"2023-03-16","hide_reason":null,"hide_reason_data":null,"logokey":"$nKzmvhaqQ7EzE3jaabr8dmWIrorn1cWzjwAOH3xOwZFCpx2ARyBjXl","name":"Phibro Animal Health","israeliacquisitions":3,"forbesranking":null,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"United States","inisraelsince":"12/2008","inisraelsincemonth":"12","isisraeli":0,"marketcapital":856660162,"marketcapitaldate":"2025-11-01T14:08:41.000Z","oneliner":"Pharmaceuticals","website":"https://www.pahc.com/","employees":"201-500","employees_exact":207,"employees_overall":"1,001-5,000","employees_overall_exact":1483,"sociallinks":{"twitter":"","youtube":"","facebook":"https://www.facebook.com/PhibroAnimalHealth","linkedin":"https://www.linkedin.com/company/41089","instagram":""},"social":["https://www.facebook.com/PhibroAnimalHealth","https://www.linkedin.com/company/41089"],"flattenedsociallinks":"https://www.facebook.com/PhibroAnimalHealth|https://www.linkedin.com/company/41089","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Phibro Animal Health Corporation is dedicated to helping meet the demand for animal protein. The company concentrates exclusively on animals for food production, and it is one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. Phibro Animal Health develops, manufactures, and markets a broad range of products for food animals including poultry, swine, beef and dairy cattle, and aquaculture, with direct sales and technical teams in 16 countries and R&D/manufacturing sites in the United States, Brazil, and Israel.\n\nPhibro Israel manufactures active pharmaceutical ingredients in Neot Hovav; produces vaccines in Beit Shemesh, and produces pharmaceuticals, disinfectants and other animal health products in Petach Tikva. Also operates Animal Health R&D and product testing in Beit Shemesh, Neot Hovav, and Maayan Tzvi.\n\nIt was established in 2009 with the acquisition of Abic's animal vaccine division from Teva Pharmaceuticals. In 2014, Phibro acquired the aquaculture assets of AquaVet Ltd, a technical consulting and contract research organization focused on the global aquaculture market.\n\nPhibro' pHi-Tech business unit of poultry vaccination management is also operating in Israel.","founded":"12/2000","team":[{"name":"Assaf  Shafran","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Kq579YJDA","bounced":false,"claimed":0,"founder":0,"urlname":"assaf-shafran","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgism2uwgM","position":"VP & General Manager, pHi-Tech","last_name":"Shafran","claimtoken":"496359c1a4f673c073c1a38c4e2a20a2b0baa43d5f48bc670537893c363d21ec","first_name":"Assaf ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/assaf-shafran-2a75974/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"AS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Jeren kedar","email":"keren.keadar@pahc.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLqvwowJDA","bounced":true,"claimed":0,"founder":0,"urlname":"keren-kedar","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgupurjgkM","position":"VP HR MACIE Region ","last_name":"kedar","claimtoken":"98bdee07de2d31b5596f4455119f55602d0dac678c0e57e6505d078c7648b8c6","first_name":"Jeren","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/keren-kedar-8abb021/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"JK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Jonathan Bendheim","email":"meytal.rosh@pahc.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLrQnOMIDA","bounced":false,"claimed":1,"founder":0,"urlname":"jonathan-bendheim-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICguuSdigoM","position":"General Manager, Israel Operations","last_name":"Bendheim","claimtoken":"ff4fd37ac928e127f4ca5841aa60b6fadf7c809c205ebd9a51a6a573bbb47587","first_name":"Jonathan","picturekey":"$CrONwWiLYBcxgGiWZ6nqjjOrQXZ83Ks8MPWcYRf46ei2cCFSc4y1TB","claimeddate":"2017-12-21","linkedinurl":"https://www.linkedin.com/in/jonathan-bendheim-530564","unsubscribed":true,"is_activeuser":1,"additionalemail":"jbendheim@gmail.com","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$CrONwWiLYBcxgGiWZ6nqjjOrQXZ83Ks8MPWcYRf46ei2cCFSc4y1TB","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"KoVax","hidden":false,"raised":"Undisclosed","founded":"2003","fullurl":"/company_page/kovax","logokey":"$NVEK4iw8z8VY04GckBbUMkV0kyjoemopP8tYexNSIRnKRnU23QLvEV","urlname":"kovax","employees":"1-10","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6A-9wJDA","description":"Vaccines for Viral and Bacterial Diseases in Fish","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":0,"logourl":"https://storage.googleapis.com/clean-finder-353810/$NVEK4iw8z8VY04GckBbUMkV0kyjoemopP8tYexNSIRnKRnU23QLvEV","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"51a873a5-485e-471b-8ebb-e59af647b15e","city":"Lod","type":["R&D"],"address":"Lod, Israel","placeid":null,"notactive":0,"openeddate":"2008-12-01","registrarid":"510608284","firstrdcenter":0,"registrarname":"Abic Biological Laboratories Ltd"},{"id":"a2044804-6061-466f-bb22-33e9bce2f284","city":"Zikhron Ya'akov","type":["R&D"],"address":"Zikhron Ya'akov, Israel","placeid":null,"notactive":1,"openeddate":"2014-02-01","registrarid":"513115725","firstrdcenter":0,"registrarname":"Aqua vet technologies Ltd"},{"id":"b9fab259-ea9e-4cac-a2d7-54dcdb08df4b","city":"Lod","type":["R&D"],"address":"Lod, Israel","placeid":null,"notactive":0,"openeddate":"2000-01-01","registrarid":"511399917","firstrdcenter":1,"registrarname":"PHIBRO ANIMAL NUTRITION LTD"},{"id":"e5491cd4-2e76-4eac-8649-78d74223d260","city":"Lod","type":["R&D"],"address":"Lod, Israel","placeid":null,"notactive":0,"openeddate":"2000-01-01","registrarid":"510057607","firstrdcenter":1,"registrarname":"PHIBRO ANIMAL HEALTH LTD"},{"id":"e5519578-dce4-4284-a4c3-133cfbb233e9","city":"Petah Tikva","type":["Sales"],"address":"HaMagshimim 7, Petach Tikva, Israel","placeid":null,"notactive":1,"openeddate":"2008-12-01","registrarid":"514212497","firstrdcenter":1,"registrarname":"Phibro Animal Health Holdings Ltd"},{"id":"nQCspUDRhDJT12GZMfpP6srdOaAoQdpDyHJE1RF9aet6Cwt7DbYZd9","city":"Lod","type":["R&D"],"address":"Lod, Israel","placeid":null,"notactive":0,"openeddate":"2015-05-01","registrarid":"515306504","firstrdcenter":1,"registrarname":null},{"id":"wA6QHmYL2tmihv2p34sXnO5IVA3AesbOEOF4WyqMSMH9BHzpUgLdTA","city":"Lod","type":null,"address":"Lod, Israel","placeid":null,"notactive":0,"openeddate":"2015-06-01","registrarid":"515306504","firstrdcenter":1,"registrarname":"PHI-TECH ANIMAL HEALTH TECHNOLOGIES"}],"officesabroad":[{"id":"rKz6yqnGx2ccGpKmdQznqzD1gdVTBuURfxUfCXQILtnZafjX5PuMZh","city":"Teaneck","address":"Teaneck, NJ, USA","country":"United States","placeid":null}]},"headquarter_address":"Teaneck, NJ, USA","news":[{"id":"wQnohu3JOZJAmDiibhBd7vHe5zaIP2973bvjYelOKWjRXOFOgG9oqZ","date":"Oct 28, 2025","link":"https://finance.yahoo.com/news/brainsway-ltd-sponsored-adr-bway-131503531.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Brainsway Ltd.","layoffs":null,"summary":"Brainsway Ltd. has experienced significant stock growth, with shares rising 11.3% over the past month and reaching a 52-week high. The company has consistently surpassed earnings expectations, reporting a recent EPS of $0.1 against a $0.07 estimate. For the current fiscal year, Brainsway is projected to achieve a 94.44% increase in EPS and a 24.5% rise in revenues. Despite its strong performance, the stocks valuation metrics suggest it trades at a premium compared to industry averages. Brainsways Zacks Rank of #2 (Buy) and its VGM Score of B indicate positive growth prospects, although its value score is moderate.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["stock","earnings","valuation","growth","momentum"],"date_of_event":"August 13, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6lDp89TgeuEAylQjUbmUGPyHzev0NX5QoPFYVS7hDVMO7LYJ92jNCx","news_summary":"Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"eJ6gRs3Do4bcVZl0O23ORbn6K6GYUVGisjnMj9PVrgdQPhmX55dOkA","date":"Sep 5, 2025","link":"https://finance.yahoo.com/news/biolife-solutions-2-other-stocks-113750437.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"undervaluation","round":null,"company":"BioLife Solutions, Inc.","layoffs":null,"summary":"BioLife Solutions, Inc., a company with a market cap of approximately $1.20 billion, develops and markets bioproduction products for the cell and gene therapy industry. Despite recent insider selling and removal from several Russell indices, BioLife Solutions is trading at $25.87, significantly below its estimated fair value of $43.71, suggesting potential undervaluation. The company has raised its 2025 revenue guidance to $100 million to $103 million, reflecting strong growth expectations. Analysts forecast robust earnings growth of 64.83% annually, indicating potential for significant increases in future results. This positions BioLife Solutions as a promising investment opportunity amidst a rising stock market.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["stock market","undervaluation","revenue growth","earnings forecast","insider selling"],"date_of_event":"September 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$1.20 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yhzhd6cFXIAHTiS9HfLVP9QkCb6izRqarSDwDzFGhVGd4oQpFwFxWl","news_summary":"BioLife Solutions And 2 Other Stocks That May Be Trading Below Their Estimated Value","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"aCgXyBY3ArGxEsxH64PcRIR7iDZlF2SR3W3YNtTquwNchivEBaqTsc","date":"Sep 2, 2025","link":"https://finance.yahoo.com/news/three-companies-may-priced-below-113759858.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"undervalued","round":null,"company":"Vertex, Inc.","layoffs":null,"summary":"As of late August 2025, the U.S. stock market is experiencing a slight pullback from record highs, with major indices showing minor declines. Despite this, Vertex, Inc. is identified as an undervalued stock, trading at $25.82 against an estimated fair value of $37.51. The company, which offers enterprise tax technology solutions, has a market cap of approximately $4.12 billion. Despite a recent net loss and lowered earnings guidance, Vertexs revenue is forecasted to grow annually by 12.5%, outpacing the broader U.S. market growth rate. Strategic enhancements in tax automation and integration with major platforms like Oracle are expected to drive future profitability improvements.","partners":"Oracle","customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["stock market","undervalued stocks","economic uncertainties","tax technology","revenue growth"],"date_of_event":"August 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$4.12 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"41WFtKtE1z4ht7R1f8Tbjy83pJTiUUyMlkUgxZCqT1M4HLuixyL2lS","news_summary":"Three Companies That May Be Priced Below Their Estimated Worth In September 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"nzFAJ0aDCVD076sXh7T2AUFUZbiX0vVWkRB7ANBKLHAIsscBTf0TOU","date":"Sep 2, 2025","link":"https://finance.yahoo.com/news/3-stocks-estimated-trading-discounts-173752609.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"undervaluation","round":null,"company":"Oddity Tech Ltd.","layoffs":null,"summary":"Oddity Tech Ltd., a consumer tech company focusing on digital-first brands in the beauty and wellness sectors, is currently trading at a significant discount to its estimated fair value. With a market cap of $3.36 billion, the company reported a strong Q2 performance, with sales rising to $241.14 million from $192.77 million year-over-year and net income increasing to $49.29 million. The companys revenue and earnings are forecasted to grow faster than the US market average, indicating potential undervaluation based on cash flows. This suggests a growth-positive outlook for Oddity Tech, as it may be poised for expansion.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","undervaluation","earnings growth","revenue increase","cash flows"],"date_of_event":"September 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2hCCbulVlc19UOC1p42DC5W9sGCeUdDHfsNl4CNEyyKMA3AYZjBmT6","news_summary":"3 Stocks Estimated To Be Trading At Discounts Of Up To 30.8%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9JRB7UHZ9gkVULRLjB8PGgHhpQApadVxRmkGOohI8X1OGOpEEgQTQ4","date":"Aug 29, 2025","link":"https://finance.yahoo.com/news/3-stocks-estimated-trading-below-173759780.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"undervalued","round":null,"company":"Phibro Animal Health Corporation","layoffs":null,"summary":"In August 2025, the U.S. stock market is experiencing a pullback, with major indices retreating as technology stocks face pressure. Amid this environment, Phibro Animal Health Corporation is highlighted as an undervalued stock, trading at $38.46 against a fair value estimate of $70.71, representing a 45.6% discount. The company, which focuses on animal health and mineral nutrition, has shown significant earnings growth, with net income rising to $48.26 million for fiscal 2025. Despite slower revenue growth compared to the market average and concerns about operating cash flow covering debt obligations, the companys future financial performance is expected to be robust.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","valuation","earnings growth","debt obligations","financial performance"],"date_of_event":"August 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$1.31 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ozdsmkArZuFzeDclbwDZ0PbeWImJoMxbx5wfwJXk5hLyareSWWtd1B","news_summary":"3 Stocks Estimated To Be Trading Below Intrinsic Value In August 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"uX5LeVUOXW0TJhL0LPMz5p5p70vzWUOnI2zZPnayVPvgz4ejOfqS4C","date":"Aug 20, 2025","link":"https://finance.yahoo.com/news/phibro-animal-health-corporation-pahc-131502233.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Phibro Animal Health","layoffs":null,"summary":"Phibro Animal Health (PAHC) has experienced a significant increase in its stock price, rising 9% over the past month and reaching a new 52-week high of $32.08. The company has consistently exceeded earnings expectations, with a recent EPS of $0.63 against a consensus estimate of $0.52. For the current fiscal year, Phibro is projected to post earnings of $2.3 per share on $1.28 billion in revenues, with further growth expected in the next fiscal year. The companys stock is considered a strong value investment, with a Zacks Rank of #2 (Buy) and a VGM Score of A. Despite its recent high, Phibros valuation metrics suggest potential for further gains.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock","earnings","valuation","growth","investment"],"date_of_event":"May 7, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gnxPbsOFUcYcbUpje0zPCPjEYuxEgMN4J3QBWykua6Txu43VfIaSCY","news_summary":"Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ypSw2mSXwMdlXoov6dbOtSsYVu46HgpbN99fyWFuqwngvQg4hdJ3Mc","date":"Jun 12, 2025","link":"https://finance.yahoo.com/news/brainsway-ltd-sponsored-adr-bway-131502550.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock-performance","round":null,"company":"Brainsway Ltd. Sponsored ADR","layoffs":null,"summary":"Brainsway Ltd. Sponsored ADR has experienced a significant increase in its stock price, reaching a new 52-week high of $12, with a 14.2% rise over the past month. The company has consistently surpassed earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0.02 in its last earnings report. For the current fiscal year, Brainsway is expected to post earnings of $0.15 per share on $50.36 million in revenues, with a projected increase in both EPS and revenues for the next fiscal year. Despite its high valuation metrics, the company holds a Zacks Rank of #2 (Buy) due to favorable earnings estimate revisions.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["stock","earnings","valuation","growth","momentum"],"date_of_event":"May 13, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ex8scPAxggvrhNQMaJgTKrbR0adMXOlLuFtxllPjjFo9dYcfbYBKss","news_summary":"Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mFMdU8cKFwg1kYQwPJ1R6PyycxO6jttiBhKCH8TskQsZiqo5laysze","date":"Apr 10, 2025","link":"https://finance.yahoo.com/news/inmode-inmd-soars-6-8-153600769.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock-performance","round":null,"company":"InMode","layoffs":null,"summary":"InModes shares rose by 6.8% to $15.46 in the last trading session, driven by a relief rally in global markets following a 90-day pause on U.S. tariff hikes. Despite a 23% loss over the past four weeks, the companys stock saw a significant volume of trades. InMode, a cosmetic surgery device maker, is expected to report quarterly earnings of $0.45 per share, unchanged from the previous year, with revenues projected to increase by 14.5% to $91.9 million. The stock holds a Zacks Rank #3 (Hold), indicating potential for future growth if earnings estimates improve.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock","earnings","revenue","tariff","market"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mqG1YggkG2H6mVBFuZOwg4QFjnYla8CPuNUH8doNVgclCRaF6siooi","news_summary":"InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"dc60cd99-4ff1-46a2-a6a5-403b22de9490","date":"Dec 6, 2018","link":"https://todaysveterinarybusiness.com/phibro-acquires-israeli-fish-vaccine-developer/","source":"todaysveterinarybusiness.com","visible":1,"analysis":{"tags":"acquisition","company":"Phibro Animal Health Corp.","layoffs":null,"summary":"Phibro Animal Health Corp. has acquired aquaculture vaccine maker KoVax Ltd., strengthening its position in fish vaccine innovation and expanding its portfolio of aquaculture products. The terms of the transaction were not disclosed. Phibro will retain the KoVax research and development team. The acquisition will allow Phibro to provide customized solutions to its customers in the aquaculture industry. KoVax is known for its KV3 vaccine, which fights koi herpes virus. The company was founded in 2003 by Orit and Yaniv Kotler.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phibro Animal Health Corp.","aquaculture","vaccine","acquisition","KoVax Ltd."],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YeY1ljxkJNI1mj31qpet1AabDRAJ8YFHzM0aJSVoKq5PThiMEuRqnS","news_summary":"Phibro acquires Israeli fish vaccine developer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"881c9198-bfbb-425a-b124-5f71bca230b4","date":"Jul 24, 2017","link":"http://www.globes.co.il/en/article-phibro-israel-signs-150m-indian-deal-1001198348","source":"www.globes.co.il","visible":1,"analysis":{"tags":"partnership","company":"Zydus Cadila","layoffs":null,"summary":"Zydus Cadila will set up a plant in India to produce Phibros vaccinations and drugs for animals. The Israeli branch of veterinary company Phibro Animal Health Corporation has signed a memorandum of understanding (MoU) with Indian company Zydus Cadila, in which the latter company will set up a plant in India to manufacture Phibros products and market them in India. Market sources estimate the value of the deal at $150 million over five years. Phibro is listed on Nasdaq with a $1.5 billion market cap.","partners":["Phibro Animal Health Corporation"],"customers":null,"investors":null,"confidence":9,"key_topics":["vaccinations","drugs for animals","plant in India","Phibro Animal Health Corporation","Zydus Cadila"],"date_of_event":"July 23, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"818bnqbVxoImP6vc2T34zR96uTIdxgr7xX7adV36zc6qJoUIwb9Lia","news_summary":"Phibro Israel signs Indian MoU","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODKja3NCAw","hub":null,"date":"1970-01-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"PAHC","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["poultry","agtech","vaccines","supplements","animal-health","veterinary","aquaculture","nutrition"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"1,001-5,000","fundingtype":"Multinational","parsedName":"Phibro Animal Health","logourl":"https://storage.googleapis.com/clean-finder-353810/$nKzmvhaqQ7EzE3jaabr8dmWIrorn1cWzjwAOH3xOwZFCpx2ARyBjXl","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$nKzmvhaqQ7EzE3jaabr8dmWIrorn1cWzjwAOH3xOwZFCpx2ARyBjXl","teamMembersNumber":3,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}